Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy (Q37113427)

18 August 2017

1 reference

title

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy (English)

1 reference

Frédérique Penault-Llorca

18 August 2017

author

4

Frédérique Penault-Llorca

0 references

Jean-Charles Soria

9

Jean-Charles Soria

0 references

Eric Deutsch

Eric Deutsch

6

0 references

Valérie Boige

Valérie Boige

5

0 references

author name string

Yohann Loriot

1

1 reference

18 August 2017

Gabriel Perlemuter

2

1 reference

18 August 2017

David Malka

3

1 reference

18 August 2017

Christophe Massard

7

1 reference

18 August 2017

Jean Pierre Armand

8

1 reference

18 August 2017

publication date

18 March 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

268-278

1 reference

Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Practical management of patients with non-small-cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

The alpha2beta1 integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase Cgamma2 in platelets

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Interstitial cells of cajal in patients with constipation due to total colonic inertia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Aspirin reduces adverse effects of gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Thromboxane A(2)-mediated Cl(-) secretion induced by platelet-activating factor in isolated rat colon

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Indications for imatinib mesylate therapy and clinical management

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Imatinib mesylate as a cause of acute liver failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Histological features of acute hepatitis after imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Imatinib mesylate-induced acute hepatitis with autoimmune features

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Fatal hepatic necrosis following imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Practical management of patients with chronic myeloid leukemia receiving imatinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1087

7 January 2021

Identifiers

DOI

10.1038/NCPONC1087

1 reference

18 August 2017

1 reference